Clinical Trial Update: Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Brentuximab Vedotin as consolidation therapy after allogeneic stem cell transplantation in relapsed or refractory classical Hodgkin lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: University of Cologne | Conditions: Classical Hodgkin Lymphoma | Phase 2 | Status: COMPLETED